Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
(HealthDay News) — The adenosine A2A receptor agonist polydeoxyribonucleotide (PDRN) facilitates healing of diabetic foot ulcers in patients with diabetes, according to a study published online January 31 in the Journal of Clinical Endocrinology & Metabolism.
Francesco Squadrito, MD, from the University of Messina in Italy, and colleagues examined the effect of PDRN on chronic ulcer healing in patients with diabetes with hard-to-heal ulcers (Wagner grade 1 or 2). Participants were randomized to receive placebo (91 patients) or PDRN (101 patients) three days a week for eight weeks.
The researchers found that 18.9% of placebo-treated patients and 37.3% of PDRN-treated patients achieved complete healing (P=0.0027). In individuals with diabetes, PDRN increased the closure of foot ulcers after eight weeks (hazard ratio, 2.20; P=0.004). For placebo and PDRN, the median time to complete wound healing was 49 and 30 days, respectively (P=0.0027). In the placebo and PDRN groups, the median epithelialized area of the ulcers was 49.3 and 82.2%, respectively.
“In conclusion, the results suggest that PDRN improves wound closure, shortens the time needed for healing, and promotes reepithelialization,” the authors write. “Therefore PDRN could represent an effective and safe treatment useful to facilitate the poor wound healing of subjects with diabetes, in addition to standard care.”
The drug was gifted by Mastelli.
